Palisade Bio, Inc. (NASDAQ: PALI) shares lost some ground Friday. The Carlsbad, Calif.-based company, a biopharmaceutical concern focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided an update on key areas of progress for its previously announced strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy.
Under the collaboration through an extensive analysis of transcriptomics datasets and clinical biomarkers, Palisade Bio and Strand have identified promising PDE4-related biomarkers associated with UC pathology, providing valuable insights for targeted therapeutic interventions.
Key areas of progress include:
Candidate Predictive Biomarker Identification:
• Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified, paving the way for the development of innovative precision medicine approaches for treatment of UC patients with PDE4-inhibitors.
Patient Stratification:
• Ongoing research focuses on refining patient selection strategies based on PDE4-related biomarkers and disease characteristics to optimize clinical outcomes for patients with UC.
• Progress has been made in refining Palisade’s precision medicine approach, integrating clinical biomarkers, disease activity measures, and transcriptomics data, to tailor personalized UC therapies.
Dr. Mitch Jones, CMO at Palisade Bio stated, “We remain committed to advancing precision medicine solutions for UC and other inflammatory indications. Collaborative efforts with Strand and other partners will continue to drive innovation and transform the landscape of UC treatment.”
PALI shares backslid eight cents, or 1.7%, to $4.68.
